Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer

Giancarlo Pruneri, Lorenzo Pignataro, Nadia Carboni, Roberto Buffa, Devrim Di Finizio, Bruno Mario Cesana, Antonino Neri

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Purpose: To investigate the prognostic relevance of p21 and p27 protein expression in laryngeal squamous cell carcinoma (LSCC). Patients and Methods: We have analyzed by immunohistochemistry p21 and p27 expression in a series of 132 patients who underwent surgical resection of their LSCC and who had previously been investigated for p53 gene mutations and cyclin D1 expression. The tumors were considered low expressors when they had ≤ 10% of p21 and ≤ 50% of p27 immunoreactive neoplastic cells. Results: In 41 cases (31.1%), p21 was expressed in ≤ 10% of neoplastic cells; in 91 cases (68.9%), it was expressed in more than 10% of neoplastic cells. In 11 cases (8.3%), p27 was expressed in less than 5% of neoplastic cells; in 39 cases (29.6%), it was expressed in 5% to 50% of neoplastic cells; and in 82 cases (62.1%), it was expressed in more than 50% of the neoplastic cells. Low levels of p21 expression were associated with poor histologic differentiation and lymph node metastases. Low levels of p27 expression were associated with tumor extension and advanced clinical stage. Expression of p21 and p27 was not correlated with p53 gene status, and low p27 expression was more frequently detected in the cyclin D1-positive cases, with a borderline level of statistical significance. At univariate analysis, anatomic site, tumor extension, clinical stage, high cyclin D1 expression, and low p27 expression were significantly associated with reduced disease-free and overall survival rates. At multivariate analysis, high cyclin D1 expression and low p27 expression were the only significant covariates. The patients with a cyclin D1+/p27- phenotype had the poorest disease-free and overall survival rates. Conclusion: Our study provides evidence that the immunohistochemical evaluation of p27 expression is a significant independent predictor of prognosis in laryngeal carcinoma.

Original languageEnglish
Pages (from-to)3150-3159
Number of pages10
JournalJournal of Clinical Oncology
Volume17
Issue number10
Publication statusPublished - Oct 1999

Fingerprint

Laryngeal Neoplasms
Cyclin D1
Cell Cycle
p53 Genes
Disease-Free Survival
Squamous Cell Carcinoma
Survival Rate
Neoplasms
Multivariate Analysis
Lymph Nodes
Immunohistochemistry
Neoplasm Metastasis
Carcinoma
Phenotype
Mutation
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. / Pruneri, Giancarlo; Pignataro, Lorenzo; Carboni, Nadia; Buffa, Roberto; Di Finizio, Devrim; Cesana, Bruno Mario; Neri, Antonino.

In: Journal of Clinical Oncology, Vol. 17, No. 10, 10.1999, p. 3150-3159.

Research output: Contribution to journalArticle

Pruneri, Giancarlo ; Pignataro, Lorenzo ; Carboni, Nadia ; Buffa, Roberto ; Di Finizio, Devrim ; Cesana, Bruno Mario ; Neri, Antonino. / Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 10. pp. 3150-3159.
@article{4ba90142c00e4d5a94b4524b4936fba3,
title = "Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer",
abstract = "Purpose: To investigate the prognostic relevance of p21 and p27 protein expression in laryngeal squamous cell carcinoma (LSCC). Patients and Methods: We have analyzed by immunohistochemistry p21 and p27 expression in a series of 132 patients who underwent surgical resection of their LSCC and who had previously been investigated for p53 gene mutations and cyclin D1 expression. The tumors were considered low expressors when they had ≤ 10{\%} of p21 and ≤ 50{\%} of p27 immunoreactive neoplastic cells. Results: In 41 cases (31.1{\%}), p21 was expressed in ≤ 10{\%} of neoplastic cells; in 91 cases (68.9{\%}), it was expressed in more than 10{\%} of neoplastic cells. In 11 cases (8.3{\%}), p27 was expressed in less than 5{\%} of neoplastic cells; in 39 cases (29.6{\%}), it was expressed in 5{\%} to 50{\%} of neoplastic cells; and in 82 cases (62.1{\%}), it was expressed in more than 50{\%} of the neoplastic cells. Low levels of p21 expression were associated with poor histologic differentiation and lymph node metastases. Low levels of p27 expression were associated with tumor extension and advanced clinical stage. Expression of p21 and p27 was not correlated with p53 gene status, and low p27 expression was more frequently detected in the cyclin D1-positive cases, with a borderline level of statistical significance. At univariate analysis, anatomic site, tumor extension, clinical stage, high cyclin D1 expression, and low p27 expression were significantly associated with reduced disease-free and overall survival rates. At multivariate analysis, high cyclin D1 expression and low p27 expression were the only significant covariates. The patients with a cyclin D1+/p27- phenotype had the poorest disease-free and overall survival rates. Conclusion: Our study provides evidence that the immunohistochemical evaluation of p27 expression is a significant independent predictor of prognosis in laryngeal carcinoma.",
author = "Giancarlo Pruneri and Lorenzo Pignataro and Nadia Carboni and Roberto Buffa and {Di Finizio}, Devrim and Cesana, {Bruno Mario} and Antonino Neri",
year = "1999",
month = "10",
language = "English",
volume = "17",
pages = "3150--3159",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer

AU - Pruneri, Giancarlo

AU - Pignataro, Lorenzo

AU - Carboni, Nadia

AU - Buffa, Roberto

AU - Di Finizio, Devrim

AU - Cesana, Bruno Mario

AU - Neri, Antonino

PY - 1999/10

Y1 - 1999/10

N2 - Purpose: To investigate the prognostic relevance of p21 and p27 protein expression in laryngeal squamous cell carcinoma (LSCC). Patients and Methods: We have analyzed by immunohistochemistry p21 and p27 expression in a series of 132 patients who underwent surgical resection of their LSCC and who had previously been investigated for p53 gene mutations and cyclin D1 expression. The tumors were considered low expressors when they had ≤ 10% of p21 and ≤ 50% of p27 immunoreactive neoplastic cells. Results: In 41 cases (31.1%), p21 was expressed in ≤ 10% of neoplastic cells; in 91 cases (68.9%), it was expressed in more than 10% of neoplastic cells. In 11 cases (8.3%), p27 was expressed in less than 5% of neoplastic cells; in 39 cases (29.6%), it was expressed in 5% to 50% of neoplastic cells; and in 82 cases (62.1%), it was expressed in more than 50% of the neoplastic cells. Low levels of p21 expression were associated with poor histologic differentiation and lymph node metastases. Low levels of p27 expression were associated with tumor extension and advanced clinical stage. Expression of p21 and p27 was not correlated with p53 gene status, and low p27 expression was more frequently detected in the cyclin D1-positive cases, with a borderline level of statistical significance. At univariate analysis, anatomic site, tumor extension, clinical stage, high cyclin D1 expression, and low p27 expression were significantly associated with reduced disease-free and overall survival rates. At multivariate analysis, high cyclin D1 expression and low p27 expression were the only significant covariates. The patients with a cyclin D1+/p27- phenotype had the poorest disease-free and overall survival rates. Conclusion: Our study provides evidence that the immunohistochemical evaluation of p27 expression is a significant independent predictor of prognosis in laryngeal carcinoma.

AB - Purpose: To investigate the prognostic relevance of p21 and p27 protein expression in laryngeal squamous cell carcinoma (LSCC). Patients and Methods: We have analyzed by immunohistochemistry p21 and p27 expression in a series of 132 patients who underwent surgical resection of their LSCC and who had previously been investigated for p53 gene mutations and cyclin D1 expression. The tumors were considered low expressors when they had ≤ 10% of p21 and ≤ 50% of p27 immunoreactive neoplastic cells. Results: In 41 cases (31.1%), p21 was expressed in ≤ 10% of neoplastic cells; in 91 cases (68.9%), it was expressed in more than 10% of neoplastic cells. In 11 cases (8.3%), p27 was expressed in less than 5% of neoplastic cells; in 39 cases (29.6%), it was expressed in 5% to 50% of neoplastic cells; and in 82 cases (62.1%), it was expressed in more than 50% of the neoplastic cells. Low levels of p21 expression were associated with poor histologic differentiation and lymph node metastases. Low levels of p27 expression were associated with tumor extension and advanced clinical stage. Expression of p21 and p27 was not correlated with p53 gene status, and low p27 expression was more frequently detected in the cyclin D1-positive cases, with a borderline level of statistical significance. At univariate analysis, anatomic site, tumor extension, clinical stage, high cyclin D1 expression, and low p27 expression were significantly associated with reduced disease-free and overall survival rates. At multivariate analysis, high cyclin D1 expression and low p27 expression were the only significant covariates. The patients with a cyclin D1+/p27- phenotype had the poorest disease-free and overall survival rates. Conclusion: Our study provides evidence that the immunohistochemical evaluation of p27 expression is a significant independent predictor of prognosis in laryngeal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0032888779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032888779&partnerID=8YFLogxK

M3 - Article

C2 - 10506612

AN - SCOPUS:0032888779

VL - 17

SP - 3150

EP - 3159

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -